BioCentury
ARTICLE | Finance

CellCentric’s magic trio

Why Morningside is backing CellCentric’s single-asset strategy

May 18, 2018 8:40 PM UTC

Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes the undisclosed venture round will be enough to get the prostate cancer compound through clinical proof-of-concept studies.

Morningside first invested in CellCentric in 2007...